Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice

https://doi.org/10.20996/1819-6446-2018-14-4-575-582

Full Text:

Abstract

The possibility of rivaroxaban using in elderly patients with non-valvular atrial fibrillation is discussed in the review. The results of ROCKET-AF randomized trial, including subgroup analysis in patients older than 75 years, are presented. The problem of unreasonable prescription of low doses of anticoagulants in real clinical practice and questions of adherence of patients to anticoagulant therapy are discussed. The results of two recent studies of actual clinical practice performed in patients over the age of 80 and 85 years, respectively, are presented as well as favorable profile of the efficacy and safety of rivaroxaban in these age groups. Rivaroxaban reduced the risk of stroke/systemic embolism by 38% and ischemic stroke by 41% with a comparable risk of major bleeding in patients older than 80 years. In another study, in patients older than 85 years in the rivaroxaban group, a 11% reduction in the risk of death from all causes, a reduction in the risk of major bleeding by 10% and an acute coronary syndrome by 14%, with similar risk of stroke/systemic embolism, clinically significant minor bleeding and a combined endpoint (stroke/systemic embolism, large bleeding, death from all causes) have been found.

About the Authors

N. M. Vorobyeva
Pirogov Russian National Research Medical University
Russian Federation

Natalya M. Vorobyeva – MD, PhD, Senior Researcher, Laboratory of Cardiovascular Aging, Russian Gerontology Clinical Research Center

Ostrovitianova ul. 1, Moscow, 117997 



O. N. kacheva
Pirogov Russian National Research Medical University
Russian Federation

Olga N. Tkacheva – MD, PhD, Professor, Director of Russian Gerontology Clinical Research Center

Ostrovitianova ul. 1, Moscow, 117997 



References

1. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34:3028-34. doi: 10.1093/eurheartj/eht356.

2. Go A.S., Hylek E.M., Phillips K.A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-5. doi: 10.1001/jama.285.18.2370.

3. Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-6. doi: 10.1161/01.CIR.0000140263. 20897.42.

4. Go A.S., Mozaffarian D., Roger V.L. et al. Heart disease and stroke statistics 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292. doi: 10.1161/ 01.cir.0000441139.02102.80.

5. Ng KH, Hart RG, Eikelboom JW. Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther. 2013 Dec;2(2):135-49. doi: 10.1007/s40119013-0019-y.

6. Olesen J.B., Lip G.Y.H., Hansen M.L. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with AF: nationwide cohort study. BMJ. 2011;342:d124. doi: 10.1136/bmj.d124.

7. Friberg L., Rosenqvist M., Lip G.Y. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298-307. doi: 10.1161/CIRCULATIONAHA.111.055079.

8. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561.

9. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi: 10.1056/NEJMoa1009638.

10. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039.

11. Halperin J.L., Hankey G.J., Wojdyla D.M. et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) Circulation. 2014;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008.

12. Turagam M.K., Velagapudi P., Flaker G.C. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging. 2015;10:1431-44. doi: 10.2147/CIA.S80641.

13. Lopes R.D., Al-Khatib S.M., Wallentin L. et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012;380:1749-58. doi: 10.1016/S0140-6736(12)60986-6.

14. Piccini J.P., Garg J., Patel M.R. et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873-80. doi: 10.1093/eurheartj/ehu083.

15. Yao X., Shah N.D., Sangaralingham L.R. et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69:2779-90. doi: 10.1016/j.jacc.2017.03.600.


For citation:


Vorobyeva N.M., kacheva O.N. Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice. Rational Pharmacotherapy in Cardiology. 2018;14(4):575-582. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-4-575-582

Views: 155


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)